A Multi-Centre Study in Patients Undergoing Total Hip Arthroplasty With the Smith+Nephew CATALYSTEM™ Primary Hip System (NCT06564636)

🧪 Interventions in This Study

• CATALYSTEM (DEVICE)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (10 Sites)

• University of California at San Francisco — San Francisco, California
• Connecticut Orthopaedic Institute — Hamden, Connecticut
• Orlando Health Inc. — Orlando, Florida
• Illinois Bone and Joint Institute — Des Plaines, Illinois
• NYU Langone Health Orthopedic Hospital — New York, New York
• Duke Health — Morrisville, North Carolina
• University of Alberta — Edmonton, Alberta
• University of British Columbia — Vancouver, British Columbia
• Concordia General Hospital — Winnipeg, Manitoba
• London Health Sciences Centre (LHSC) — London, Ontario

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Total Hip Arthroplasty (THA)

• Suzetrigine in Total Hip Arthroplasty — New York, New York

Explore by condition: All Total Hip Arthroplasty (THA) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.